ANDA filing not “willful infringement”
Executive Summary
The filing of an ANDA cannot constitute "willful infringement" under Waxman/ Hatch, a federal appeals court rules July 27. Federal Circuit reverses a Chicago judge's decision ordering Apotex to pay GlaxoSmithKline attorneys' fees in a Ceftin patent dispute (1"The Pink Sheet" June 2, 2003, p. 29). Apotex was enjoined from marketing its generic until the patents expired in July 2003...
You may also be interested in...
Generic Firms Warned Of First-To-File Risk: Willful Infringement Cases Rising
The pressure on generic companies to be first-to-file in patent challenges will lead to a "boom" in willful infringement cases against generics makers, an industry attorney maintains
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.